CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

近年来，基于CRISPR的基因编辑技术在生命科学领域掀起了一场革命，不仅极大地推动了基础研究的发展，也在临床治疗、农业育种、生态治理、工业微生物技术和合成生物学等领域取得了突破性进展。然而，随着对CRISPR相关蛋白（Cas蛋白）功能的持续深入挖掘 ...

Scribe highlights latest data on Lp(a)-lowering therapy and novel AI platform for next-generation CRISPR-based therapeutics at two premier conferences ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...

VedaBio has entered into agreement with Mammoth Biosciences to enhance its CRISPR-based molecular detection platform for ...

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...

(Nanowerk News) The Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) has spearheaded the development of a novel analysis service platform named CRISPRimmunity. This ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...